	US 11,871,775 B2
	Method of inhibiting oral pathogens
Pei-Shan Hsieh, Tainan (TW); Chung-Wei Kuo, Tainan (TW); Yi-Chun Tsai, Tainan (TW); Hsieh-Hsun Ho, Tainan (TW); and Yi-Wei Kuo, Tainan (TW)
Assigned to GLAC BIOTECH CO., LTD., Tainan (TW)
Filed by GLAC BIOTECH CO., LTD., Tainan (TW)
Filed on Nov. 15, 2019, as Appl. No. 16/685,445.
Application 16/685,445 is a continuation of application No. 15/867,301, filed on Jan. 10, 2018, abandoned.
Claims priority of application No. 106102613 (TW), filed on Jan. 24, 2017.
Prior Publication US 2020/0100536 A1, Apr. 2, 2020
Int. Cl. A23L 33/135 (2016.01); A61Q 11/00 (2006.01); A61K 35/747 (2015.01); A61P 1/02 (2006.01); A61K 8/99 (2017.01); A61K 45/06 (2006.01); A61Q 17/00 (2006.01)

CPC A23L 33/135 (2016.08) [A61K 8/99 (2013.01); A61K 35/747 (2013.01); A61K 45/06 (2013.01); A61P 1/02 (2018.01); A61Q 11/00 (2013.01); A61Q 17/005 (2013.01); A23V 2002/00 (2013.01)]

14 Claims

1. A method of inhibiting oral pathogens comprising administering to a human subject in need thereof a composite comprising:

an isolated Lactobacillus paracasei ET-66 strain, CGMCC No. 13514; and

an excipient, diluent, or carrier, which is physiologically or medically acceptable,

wherein a number of the isolated Lactobacillus paracasei ET-66 strain, CGMCC No. 13514 is over 10⁶CFU.